Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes.

Gu C, Zhou G, Noble NA, Border WA, Cheung AK, Huang Y.

J Renin Angiotensin Aldosterone Syst. 2014 Jun;15(2):177-89. doi: 10.1177/1470320312466127. Epub 2012 Dec 4.

PMID:
23223090
2.

Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-β1 and PAI-1 expression in renal mesangial cells.

Zhang J, Wu J, Gu C, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2012 Jul 1;303(1):F11-20. doi: 10.1152/ajprenal.00050.2012. Epub 2012 Apr 25.

3.

Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis.

Zhang J, Gu C, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2011 Oct;301(4):F723-32. doi: 10.1152/ajprenal.00271.2011. Epub 2011 Jul 27.

4.

Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis.

Zhang J, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2010 Mar;298(3):F579-88. doi: 10.1152/ajprenal.00548.2009. Epub 2009 Dec 23.

5.

Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis.

Huang Y, Border WA, Lawrence DA, Noble NA.

Am J Physiol Renal Physiol. 2009 Oct;297(4):F1045-54. doi: 10.1152/ajprenal.00024.2009. Epub 2009 Jul 22.

6.

Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells.

Zhang J, Noble NA, Border WA, Owens RT, Huang Y.

Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E810-9. doi: 10.1152/ajpendo.90264.2008. Epub 2008 Jul 29.

7.

Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells.

Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y.

Am J Physiol Renal Physiol. 2008 Jun;294(6):F1287-95. doi: 10.1152/ajprenal.00017.2008. Epub 2008 Mar 26.

8.

A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA.

J Am Soc Nephrol. 2008 Feb;19(2):329-38. doi: 10.1681/ASN.2007040510. Epub 2008 Jan 23.

9.

Functional renin receptors in renal mesangial cells.

Huang Y, Border WA, Noble NA.

Curr Hypertens Rep. 2007 Apr;9(2):133-9. Review.

PMID:
17442225
10.

Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.

Huang Y, Noble NA, Zhang J, Xu C, Border WA.

Kidney Int. 2007 Jul;72(1):45-52. Epub 2007 Mar 28.

11.

Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis.

Huang Y, Border WA, Lawrence DA, Noble NA.

Kidney Int. 2006 Aug;70(3):515-22. Epub 2006 Jun 21.

12.

Perspectives on blockade of TGFbeta overexpression.

Huang Y, Border WA, Noble NA.

Kidney Int. 2006 May;69(10):1713-4.

13.
14.

Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect.

Yu L, Border WA, Anderson I, McCourt M, Huang Y, Noble NA.

Kidney Int. 2004 Nov;66(5):1774-84.

15.

Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells.

Gaedeke J, Noble NA, Border WA.

Kidney Int. 2004 Jul;66(1):112-20.

16.

Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury.

Aben JA, Hoogervorst DA, Paul LC, Borrias MC, Noble NA, Border WA, Bruijn JA, de Heer E.

J Am Soc Nephrol. 2003 Sep;14(9):2264-70.

17.

TGF-beta isoforms in renal fibrogenesis.

Yu L, Border WA, Huang Y, Noble NA.

Kidney Int. 2003 Sep;64(3):844-56.

18.

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.

Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA.

J Clin Invest. 2003 Aug;112(3):379-88.

19.

L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.

Peters H, Border WA, Rückert M, Krämer S, Neumayer HH, Noble NA.

Kidney Int. 2003 Apr;63(4):1382-92.

20.

Angiotensin II and progressive renal insufficiency.

Gaedeke J, Noble NA, Border WA.

Curr Hypertens Rep. 2002 Oct;4(5):403-7. Review.

PMID:
12217260
21.

Therapeutic strategies to halt renal fibrosis.

Yu L, Noble NA, Border WA.

Curr Opin Pharmacol. 2002 Apr;2(2):177-81. Review.

PMID:
11950630
22.

Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases.

Border WA, Noble N.

Semin Nephrol. 2001 Nov;21(6):563-72. Review.

PMID:
11709804
23.

Angiotensin II, TGF-beta and renal fibrosis.

Gaedeke J, Peters H, Noble NA, Border WA.

Contrib Nephrol. 2001;(135):153-60. Review. No abstract available.

PMID:
11705280
24.

t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.

Haraguchi M, Border WA, Huang Y, Noble NA.

Kidney Int. 2001 Jun;59(6):2146-55.

25.
26.

Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse.

Border WA, Noble NA.

Am J Kidney Dis. 2000 Apr;35(4):773-6. No abstract available.

PMID:
10739804
28.

Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis.

Peters H, Border WA, Noble NA.

Nephrol Dial Transplant. 1999;14 Suppl 4:22-3. No abstract available.

PMID:
10463199
29.

From rats to man: a perspective on dietary L-arginine supplementation in human renal disease.

Peters H, Border WA, Noble NA.

Nephrol Dial Transplant. 1999 Jul;14(7):1640-50. Review.

PMID:
10435871
30.
31.

Increased levels of transforming growth factor-beta in HIV-associated nephropathy.

Yamamoto T, Noble NA, Miller DE, Gold LI, Hishida A, Nagase M, Cohen AH, Border WA.

Kidney Int. 1999 Feb;55(2):579-92.

32.

Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis.

Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, Imai E.

Kidney Int. 1999 Feb;55(2):465-75.

33.
34.

Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy.

Border WA, Noble NA.

Kidney Int. 1998 Oct;54(4):1390-1. Review. No abstract available.

35.

Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis.

Border WA, Noble NA.

Hypertension. 1998 Jan;31(1 Pt 2):181-8. Review.

PMID:
9453300
36.

Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?

Noble NA, Border WA.

Semin Nephrol. 1997 Sep;17(5):455-66. Review.

PMID:
9316214
37.

Transforming growth factor-beta in human glomerular injury.

Peters H, Noble NA, Border WA.

Curr Opin Nephrol Hypertens. 1997 Jul;6(4):389-93. Review.

PMID:
9263690
38.

TGF-beta in kidney fibrosis: a target for gene therapy.

Border WA, Noble NA.

Kidney Int. 1997 May;51(5):1388-96. Review. No abstract available.

39.

Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells.

Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA.

Kidney Int. 1997 Mar;51(3):664-71.

40.

Transforming growth factor beta in diabetic nephropathy.

Border WA, Yamamoto T, Noble NA.

Diabetes Metab Rev. 1996 Dec;12(4):309-39. Review. No abstract available.

PMID:
9013074
41.

L-arginine metabolism in immune-mediated glomerulonephritis in the rat.

Ketteler M, Ikegaya N, Brees DK, Border WA, Noble NA.

Am J Kidney Dis. 1996 Dec;28(6):878-87.

PMID:
8957040
42.

Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy.

Shihab FS, Andoh TF, Tanner AM, Noble NA, Border WA, Franceschini N, Bennett WM.

Kidney Int. 1996 Apr;49(4):1141-51.

43.

Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney.

Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA.

Nat Med. 1996 Apr;2(4):418-23.

PMID:
8597951
44.

Expression of transforming growth factor-beta isoforms in human glomerular diseases.

Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, Border WA.

Kidney Int. 1996 Feb;49(2):461-9.

45.

Targeting TGF-beta for treatment of disease.

Border WA, Noble NA.

Nat Med. 1995 Oct;1(10):1000-1. No abstract available.

PMID:
7489351
46.

Fibrosis linked to TGF-beta in yet another disease.

Border WA, Noble NA.

J Clin Invest. 1995 Aug;96(2):655-6. No abstract available.

47.

Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts.

Shihab FS, Yamamoto T, Nast CC, Cohen AH, Noble NA, Gold LI, Border WA.

J Am Soc Nephrol. 1995 Aug;6(2):286-94.

48.

TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention.

Border WA, Noble NA, Ketteler M.

Kidney Int Suppl. 1995 Jun;49:S59-61. Review. No abstract available.

PMID:
7674597
49.

L-arginine may mediate the therapeutic effects of low protein diets.

Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4552-6.

50.

Gallium citrate Ga 67 scanning in acute renal failure.

Border WA, Holbrook JH, Peterson MC.

West J Med. 1995 May;162(5):477-8. No abstract available.

Supplemental Content

Loading ...
Support Center